VENTURE CAPITAL:Archimedes Does Some MathBiopharma’s funding round is the largest private European financing in 15 years. Archimedes Pharma, a U.K.-based specialty pharma raised about $98 million and appointed a new CEO ahead of establishing U.S. commercial operations. Novo Growth Equity, funded by Novo A/S, debuted on the venture scene by leading the round, which was announced March 2. Warburg Pincus, a global private equity firm also participated. Archimedes says the funding is the largest raised by a private European biopharma company in the last 15 years. Read More
|